Hypomethylation of the LH/choriogonadotropin receptor promoter region is a potential mechanism underlying susceptibility to polycystic ovary syndrome

Endocrinology

Volumn 155, Issue 4, 2014, Pages 1445-1452

  Wang, Peng ^a,b,c,d   Zhao, Han ^a,b,c,d   Li, Tao ^a   Zhang, Wei ^a   Wu, Keliang ^a,b,c,d   Li, Mei ^a,b,c,d   Bian, Yuehong ^a,b,c,d   Liu, Hongbin ^a,b,c,d   Ning, Yunna ^a,b,c,d   Li, Guangyu ^a,b,c,d   Chen, Zi Jiang ^a,b,c,d,e  

^a SHANDONG UNIVERSITY   (China)

^b NATIONAL RESEARCH CENTER FOR ASSISTED REPRODUCTIVE TECHNOLOGY AND REPRODUCTIVE GENETICS   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d Shandong Provincial Key Laboratory of Reproductive Medicine   (China)

^e SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BISULFITE; LUTEINIZING HORMONE RECEPTOR; TESTOSTERONE;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; CPG ISLAND; DNA FLANKING REGION; DNA METHYLATION; EXON; FEMALE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GRANULOSA CELL; HUMAN; HYPOMETHYLATION; MAJOR CLINICAL STUDY; MOLECULAR CLONING; OVARY POLYCYSTIC DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

ADULT; COHORT STUDIES; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GRANULOSA CELLS; HUMANS; MUTATION; POLYCYSTIC OVARY SYNDROME; PROMOTER REGIONS, GENETIC; RECEPTORS, LH; SEQUENCE ANALYSIS, DNA; TRANSCRIPTION, GENETIC;

EID: 84897879741     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1764     Document Type: Article

References (38)

1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89:2745-2749. (Pubitemid 38766360)
2. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC. PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. BJOG. 2006;113:1210-1217. (Pubitemid 44401217)
3. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003;361:1810-1812. (Pubitemid 36638434)
4. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95:2038-2049.
5. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011;43:55-59.
6. Mutharasan P, Galdones E, Peñalver Bernabé BP, et al. Evidence for chromosome 2p16.3 polycystic ovary syndrome susceptibility locus in affected women of European ancestry. J Clin Endocrinol Metab. 2013;98:E185-E190.
7. Shi Y, Zhao H, Shi Y, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012;44:1020-1025.
8. Rosenthal IM, Refetoff S, Rich B, et al. Response to challenge with gonadotropin-releasing hormone agonist in a mother and her two sons with a constitutively activating mutation of the luteinizing hormone receptor-a clinical research center study. J Clin Endocrinol Metab. 1996;81:3802-3806. (Pubitemid 26339957)
9. Zhang Y, Fatima N, Dufau ML. Coordinated changes in DNA methylation and histone modifications regulate silencing/derepression of luteinizing hormone receptor gene transcription. Mol Cell Biol. 2005;25:7929-7939. (Pubitemid 41262988)
10. Zhu JQ, Zhu L, Liang XW, Xing FQ, Schatten H, Sun QY. Demethylation of LHR in dehydroepiandrosterone-induced mouse model of polycystic ovary syndrome. Mol Hum Reprod. 2010;16:260-266.
11. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-47.
12. Jeppesen JV, Kristensen SG, Nielsen ME, et al. LH-receptor gene expression in human granulosa and cumulus cells from antral and preovulatory follicles. J Clin Endocrinol Metab. 2012;97:E1524-E1531.
13. Matsubara H, Ikuta K, Ozaki Y, et al. Gonadotropins and cytokines affect luteal function through control of apoptosis in human luteinized granulosa cells. J Clin Endocrinol Metab. 2000;85:1620-1626. (Pubitemid 32289509)
14. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18:1427-1431. (Pubitemid 35414532)
15. Dufau ML, Tsai-Morris CH, Hu ZZ, Buczko E. Structure and regulation of the luteinizing hormone receptor gene. J Steroid Biochem Mol Biol. 1995;53:283-291.
16. Robertson KD. DNA methylation and human disease. Nat Rev Genet. 2005;6:597-610. (Pubitemid 41044297)
17. Li Z, Huang H. Epigenetic abnormality: a possible mechanism underlying the fetal origin of polycystic ovary syndrome. Med Hypotheses. 2008;70:638-642. (Pubitemid 351193031)
18. Abbott DH, Barnett DK, Bruns CM, Dumesic DA. Androgen excess fetal programming of female reproduction: a developmental aetiology for polycystic ovary syndrome? Hum Reprod Update. 2005;11:357-374. (Pubitemid 40895465)
19. Franks S. Animal models and the developmental origins of polycystic ovary syndrome: increasing evidence for the role of androgens in programming reproductive and metabolic dysfunction. Endocrinology. 2012;153:2536-2538.
20. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:161-165. (Pubitemid 34084686)
21. Echiburú B, Pérez-Bravo F, Maliqueo M, et al. CAG repeat polymorphism of androgen receptor gene and X-chromosome inactivation in daughters of women with polycystic ovary syndrome (PCOS): relationship with endocrine and metabolic parameters. Gynecol Endocrinol. 2012;28:516-520.
22. Shah NA, Antoine HJ, Pall M, Taylor KD, Azziz R, Goodarzi MO. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab. 2008;93:1939-1945. (Pubitemid 351656541)
23. Xu N, Azziz R, Goodarzi MO. Epigenetics in polycystic ovary syndrome: a pilot study of global DNA methylation. Fertil Steril. 2010;94:781-783.e1.
24. Sang Q, Zhang S, Zou S, et al. Quantitative analysis of follistatin (FST) promoter methylation in peripheral blood of patients with polycystic ovary syndrome. Reprod Biomed Online. 2013;26:157-163.
25. Geng Y, Tsai-Morris CH, Zhang Y, Dufau ML. The human luteinizing hormone receptor gene promoter: activation by Sp1 and Sp3 and inhibitory regulation. Biochem Biophys Res Commun. 1999;263:366-371. (Pubitemid 29467202)
26. Jakimiuk AJ, Weitsman SR, Navab A, Magoffin DA. Luteinizing hormone receptor, steroidogenesis acute regulatory protein, and steroidogenic enzyme messenger ribonucleic acids are overexpressed in thecal and granulosa cells from polycystic ovaries. J Clin Endocrinol Metab. 2001;86:1318-1323. (Pubitemid 32323023)
27. Lister R, Pelizzola M, Dowen RH, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. Nature. 2009;462:315-322.
28. Rakyan VK, Down TA, Balding DJ, Beck S. Epigenome-wide association studies for common human diseases. Nat Rev Genet. 2011;12:529-541.
29. Suter CM, Martin DI, Ward RL. Germline epimutation of MLH1 in individuals with multiple cancers. Nat Genet. 2004;36:497-501. (Pubitemid 38620035)
30. Balen AH. Hypersecretion of luteinizing hormone and the polycystic ovary syndrome. Hum Reprod. 1993;8(suppl 2):123-128. (Pubitemid 23337190)
31. Shaw HJ, Hillier SG, Hodges JK. Developmental changes in luteinizing hormone/human chorionic gonadotropin steroidogenic responsiveness in marmoset granulosa cells: effects of follicle-stimulating hormone and androgens. Endocrinology. 1989;124:1669-1677. (Pubitemid 19105431)
32. Wang C, Hsueh AJ, Erickson GF. LH stimulation of estrogen secretion by cultured rat granulosa cells. Mol Cell Endocrinol. 1981;24:17-28. (Pubitemid 11020451)
33. Kammerman S, Ross J. Increase in numbers of gonadotropin receptors on granulosa cells during follicle maturation. J Clin Endocrinol Metab. 1975;41:546-550.
34. Willis DS, Watson H, Mason HD, Galea R, Brincat M, Franks S. Premature response to luteinizing hormone of granulosa cells from anovulatory women with polycystic ovary syndrome: relevance to mechanism of anovulation. J Clin Endocrinol Metab. 1998;83:3984-3991. (Pubitemid 28513584)
35. Hillier S. Current concepts of the roles of follicle stimulating hormone and luteinizing hormone in folliculogenesis. Hum Reprod. 1994;9:188-191. (Pubitemid 24076735)
36. Kumar P, Sait SF. Luteinizing hormone and its dilemma in ovulation induction. J Hum Reprod Sci. 2011;4:2-7.
37. Yong E, Baird D, Hillier S. Mediation of gonadotrophin-stimulated growth and differentiation of human granulosa cells by adenosine-3′,5′- monophosphate: one molecule, two messages. Clin Endocrinol (Oxf). 1992;37:51-58.
38. Yong EL, Baird DT, Yates R, Reichert LE Jr, Hillier SG. Hormonal regulation of the growth and steroidogenic function of human granulosa cells. J Clin Endocrinol Metab. 1992;74:842-849.